California-based real-world information platform Atropos Health has secured $33 million in Sequence B funding.
Valtruis led the funding spherical, which included new buyers McKesson Ventures, Merck GHI Fund and Cencora Ventures.
Present buyers Emerson Collective, Breyer Capital, and Presidio Ventures additionally participated within the spherical.
Mike Spadafore, managing director of Valtruis, will be a part of the corporate’s board of administrators.
WHAT IT DOES
The California-based firm, based in 2019, affords AI improvements, proof technology, analytics augmentation and information analysis to assist physicians entry real-world proof to information scientific selections and analysis.
The corporate additionally affords a platform dubbed ChatRWD, an LLM-powered chat software for scientific analysis that goals to eradicate hallucination danger by using the corporate’s real-world information platform, GENEVA OS.
Atropos will use the funds to develop into oncology and specialty care with the assistance of one in all its new buyers Cencora, previously AmerisourceBergen. Cencora is a drug wholesale firm and contract analysis group.
The funds can even assist the total launch of ChatRWD.
“The way forward for value-based care is about making evidence-based selections; persevering with to ship high-quality proof to well being techniques permits them to implement applications and processes that drive distinctive affected person outcomes whereas minding the underside line,” Dr. Brigham Hyde, CEO and cofounder of Atropos Well being, advised MobiHealthNews in an electronic mail.
“Proof is extra vital than ever, particularly in the case of oncology care. It is evolving consistently, and the stakes are extremely excessive. By investing in our options and sustaining transparency in our methodologies, we empower well being system and life science companions to make selections primarily based on real-world proof for most cancers sufferers and all sufferers, fostering really customized medication and remodeling the panorama of healthcare.”
MARKET SNAPSHOT
Final 12 months, Atropos introduced it completed a strategic financing round, a 12 months after securing $14 million in a Series A funding round.
The corporate additionally announced a partnership with data-sharing know-how platform Datavant, that may permit every firm’s members to entry the opposite firm’s choices.
Earlier this 12 months, Atropos introduced that healthcare information analytics firm Arcadia joined its well being portfolio. This might permit Arcadia’s supplier clients and life sciences customers to entry its datasets for value-based care and scientific decision-making.
The corporate has additionally partnered with scientific analytics and affected person chart summarization firm KAID Well being, healthcare information firm SEQSTER and Janssen Research & Development, a Johnson & Johnson firm.
